Evidence map›Paper›PMID 39883196›Full record

SynthesisWorld journal of urology2025

Utility of MRI in NMIBC and feasibility of avoiding Re-TURB in carefully selected patients: a systematic review.

A Saouli, I Zerda, K Elkhader, X Durand, M Ariane, Fahad Quhal, Masoud Al Shammari, Roberto Contieri, Ala Chebbi

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A SaouliDepartment of Urology, Centre Hospitalier Régional Moulay Youssef, Rabat, Morocco. Amine.saouli0@gmail.com.
I ZerdaDepartment of Urology B, Ibn Sina Hospital, CHU Ibn Sina, Rabat, Morocco.
K ElkhaderDepartment of Urology B, Ibn Sina Hospital, CHU Ibn Sina, Rabat, Morocco.
X DurandDepartment of Urology, Paris Saint-Joseph Hospital, Paris, France.
M ArianeDepartment of Urology, Clinique de la Région Mantaise, Mantes-la-Jolie, France.
Fahad QuhalDepartment of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Masoud Al ShammariDepartment of Urology, King Fahad Hospital of University in Khobar, Al Khobar, Saudi Arabia.
Roberto ContieriDepartment of Urology, IRCCS Humanitas Research Hospital, Rozzano, 20089, Italy.
Ala ChebbiDepartment of Urology, Paris Saint-Joseph Hospital, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis systematic review was conducted to synthesize current research on the role of repeated transurethral resection of the bladder (re-TURB) and the emerging use of magnetic resonance imaging (MRI) in discerning patient suitability for safely foregoing this procedure. EVIDENCE ACQUISITION: Employing a methodical literature search, we consulted several bibliographic databases including PubMed, Science Direct, Scopus, and Embase. The review process adhered strictly to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines. EVIDENCE SYNTHESIS: We evaluated data from 667 patients (mean age 65.8 years; age range 59-75 years) who underwent MRI prior to potential re-TURB. The gap between initial TURB and MRI was reported as 42 days in one study, while the interval between MRI and subsequent cystoscopy, with or without biopsy, varied from 21 days to 3 months. Initial TURB pathology for non-muscle invasive bladder cancer (NMIBC) patients identified stage Ta in 177 (42.5%) and T1 in 246 (57.5%) patients across three studies. High-grade and low-grade pathologic classifications were reported in 377 (64.5%) and 207 (35.5%) patients respectively in two studies. The VI-RADS scoring system's sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the detection of bladder cancer recurrence were 89%, 85.5%, 82.7%, and 96%, respectively. A total of 365 patients (54.7%) underwent re-TUR. Among NMIBC patients, re-TUR pathology revealed Ta in 22 cases (5.4%) and pT1 in 179 cases (44%) with VI-RADS 1-2, while no cases of Ta (0%) and 37 cases of T1 (9%) were reported with VI-RADS 4-5, as documented in two studies. Notably, only 69 patients (10.7%) were identified as having MIBC across all studies.

conclusionMRI is demonstrating reliability as a diagnostic tool for non-muscle invasive bladder cancers. The VI-RADS scoring system appears to be a promising approach in selecting patients for re-TURB. DW-MRI may serve as a primary diagnostic examination for patient follow-up post-TURB.

Indexed as

CystectomyMagnetic Resonance ImagingPatient SelectionUrinary Bladder NeoplasmsAgedFeasibility StudiesHumansMiddle AgedNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsReoperationBladder cancerFollow-upMRIRe-TURB

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.